Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Terminated 3Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 8Lymphoma, Follicular 8Lymphoma 7Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Recurrence 4Myeloproliferative Disorders 4Lymphoma, Mantle-Cell 4Primary Myelofibrosis 3Hereditary Sensory and Autonomic Neuropathies 2Advanced Malignancies 2Unresectable or Metastatic Solid Tumors 1Solid Tumors 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1B-Cell Malignancies 1

Interventions

ruxolitinib 21Azacitidine 5ponatinib 4parsaclisib 4nilotinib 4itacitinib 4anagrelide 3Phlebotomy 3Imatinib Mesylate 3INCB039110 3Aspirin 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3venetoclax 2pemigatinib 2luspatercept 2imetelstat 2givinostat hydrochloride 2givinostat 2fedratinib 2asciminib 2INCB057643 2Gemcitabine 2GRN163L peptide 2spartalizumab 1sonidegib 1selinexor 1sabatolimab 1rucaparib 1pembrolizumab 1navitoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Myeloproliferative Disorders × parsaclisib × Clear all
NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Incyte Corporation

Phase 2 Active not recruiting
112 enrolled
LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT04551066 2025-10-21

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Incyte Corporation

Phase 3 Terminated
252 enrolled 18 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Incyte Corporation

Phase 3 Terminated
177 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Incyte Corporation

Phase 2 Terminated
74 enrolled 40 charts
Myeloid

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡